{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-032281","form_type":"8-K","ticker":"LUCD","cik":"0001799011","company_name":"Lucid Diagnostics Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.161786+00:00","generated_at":"2026-06-21T20:57:53.908627+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lucid Diagnostics Q3 net loss $14.3M; EsoGuard test volume up 436% YoY to 1,088","bullets":["GAAP net loss attributable to common stockholders $14.3M (-$0.39/share); non-GAAP adjusted loss $10.2M (-$0.28/share).","EsoGuard test volume 1,088 in Q3 (+28% sequential, +436% YoY); EsoGuard-related revenue $0.1M.","Cash and equivalents $26.9M at Sep 30, 2022, down from $53.7M at Dec 31, 2021; committed equity facility up to $50M.","Sales team at 37, target 58 early 2023. 13 Lucid Test Centers in 11 states; 3 more by year-end.","EsoCheck production moved to Coastline International; expects 60% reduction in per-unit manufacturing cost."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-032281","json":"https://secwatch.observer/filing/0001493152-22-032281.json","markdown":"https://secwatch.observer/filing/0001493152-22-032281.md","text":"https://secwatch.observer/filing/0001493152-22-032281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799011/000149315222032281/0001493152-22-032281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799011/000149315222032281/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:57:53.908627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d82898b005ccfeb108afe13fbc2ddc6333a4a44","claim":"Lucid Diagnostics Inc. reported the three months ended September 30, 2022 results: revenue $0.1 million, net income approximately $14.3 million, EPS $(0.39) per common share.","evidence_excerpt":"For the three months ended September 30, 2022, EsoGuard related revenues were $0.1 million. Operating expenses were approximately $14.4 million, including stock-based compensation expenses of $3.6 million. GAAP net loss attributable to common stockholders was approximately $14.3 million, or $(0.39) per common share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799011/000149315222032281/0001493152-22-032281-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$0.1 million"},{"label":"Net income","value":"approximately $14.3 million"},{"label":"EPS","value":"$(0.39) per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}